Page 6 - பெருநிறுவன வாழ்க்கைத்தொழில்கள் அரசு உறவுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2020 Financial Results DUBLIN, Feb. 23, 2021 /PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2020 and provided financial guidance for 2021. In 2020, we made meaningful progress toward our goal to significantly grow and diversify 2022 revenues from products launched since 2019, highlighted by the strong execution of our U.S. launches of both Zepzelca and Xywav. Despite the pandemic, we delivered important new treatment options for patients, ensured the well-being of employees and generated significant value for shareholders. We meaningfully increased revenues, executed three product launches, advanced early- and late-stage clinical trials and added multiple new novel product candidates to our expanding pipeline, all of which exemplifies our highly effective operational execution throughout 2020, while continuing our transformation as an inno

United statesJacqueline kirbyAndrean flynnOxybate xyremJennifer cookRobert iannoneMarkd smithErwinaze erwinaseEpidiolex epidyolexBruce cozaddOncology centerCodiak biosciences incJazz pharmaceuticalsGw pharmaceuticalsCavion incPrnewswire jazz pharmaceuticals